Browse drugs

…HBsAg levels and sustained viral suppression in mice.Conclusion Glycine has the potential to reduce HBV cccDNA levels by stimulating he…

…d 16.3% at 48 weeks of peg-IFN therapy, respectively.Conclusion Peg-IFN add-on results in HBsAg loss in 18% of patients with SOT HBsAg<…

…n of CD62L (>96%). Supplementing Synecta T1 with either soluble IL-7 and IL-15 or Synecta CK1 further enhanced expansion, with Synec…

… which can be leveraged therapeutically. These findings support SyntiGen as a promising strategy for personalized and localized cancer i…

…nicalTrials.gov between 2014 and 2024 evaluating approved ICIs (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab,…

…de l’Université de Montréal (CHUM), a phase I clinical trial of KAN-004 in patients with irColitis is planned to begin in Q4 2025.…

… M, PHan V, Weinberg JB, Palmares TM, Song A, Lee S, Mortara L. Ruxolitinib in treatment of refractory hypereosinophilic syndrome. Journal …

…cancer immunotherapy clinical trials (OAK and POPLAR, comparing atezolizumab to docetaxel in non-small cell lung cancer) as well as a separa…

…tic activity comparable to the CD19 BiTE molecule. In addition, ASKG193 was well tolerated in vivo.Conclusions In summary, the masked C…

…ted, and TCRm designs. This versatility broadens the utility of TriTCE Co-Stim to varied tumor settings and patient populations, while minimiz…

…solated and dissociated ovarian tumor biopsies, the addition of BMX-A induced tumor resident MAIT cells to proliferate and serial kil…

…onclusions Together, we demonstrate a novel 1000-plex solution, Omni 1000, with content balancing critical targets and biological breadth…